Outcome of Board Meeting held today, i.e. 09th June, 2026 for approval of financials results for the half year and year ended 31st March, 2026.

Emphasis Of MatterPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.9%Reaction day

₹43.65

prior close

₹43.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.4%+11.4% vs market

Pharmaceuticals peers, median of 164sector-0.6%+10.5% vs sector

On the reaction day the stock moved 11.4 pts more than Nifty Microcap 250 and 10.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

-1.1

15m

-1.1

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.9-1.4+11.4-0.6+10.5

Next day

+8.3-2.5+10.9-1.4+9.7

+6.5+0.4+6.1-0.1+6.7

+1.8+2.2-0.3+0.4+1.5

+2.2+2.7-0.6+0.1+2.1

-0.9+3.9-4.8+0.1-1.0

-1.9+5.2-7.1+0.4-2.3

15d

-3.3+6.5-9.7+3.9-7.2

-5.6+6.9-12.5+4.3-9.9

-4.0+9.1-13.2+4.9-8.9

-15.8+11.6-27.4+8.7-24.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Goldline Pharmaceutical Limited's Board approved audited standalone financial results for FY26 (year ended 31 March 2026) at its meeting on 9 June 2026. Revenue from operations grew to ₹3,119.76 lakhs from ₹2,805.57 lakhs in FY25, an increase of about 11.2%. Profit after tax jumped to ₹411.71 lakhs from ₹283.43 lakhs, a growth of around 45.3%, with EPS rising to ₹5.97 from ₹4.11. The company also appointed M/s. Kunal Dutt & Associates as Internal Auditor from FY27. The company recently got listed on the BSE SME platform on 19 May 2026, shortly after the reporting period. The auditor issued an unmodified opinion with an emphasis of matter noting the recent listing.

Likely market impact

Strong PAT growth of ~45% on moderate revenue growth signals healthy margin expansion, which is positive for shareholders. The recently listed SME status (May 2026) means this is the company's first reported full-year results post-listing, providing initial visibility into the business.